Interleukins 18 and 21: Biology, mechanisms of action toxicity, and clinical activity

Interleukins 18 and 21 have been described, and the effect of each upon immune response and experimental tumors in animals has been the subject of much recent work. Both interleukins have shown antitumor effects in animals, which in some models are striking for their duration, specificity, and abili...

Full description

Saved in:
Bibliographic Details
Published inCurrent oncology reports Vol. 8; no. 2; pp. 114 - 119
Main Authors Logan, Theodore F., Robertson, Michael J.
Format Journal Article
LanguageEnglish
Published United States Springer Nature B.V 01.03.2006
Subjects
Animals
Antigens, Neoplasm - immunology
Antineoplastic Agents - immunology
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antitumor activity
Clinical trials
Clinical Trials as Topic
Drug Evaluation, Preclinical
Humans
Immune response
Immunity - immunology
Immunity, Innate - immunology
Interleukin-18 - immunology
Interleukin-18 - pharmacology
Interleukin-18 - therapeutic use
Interleukins
Interleukins - immunology
Interleukins - pharmacology
Interleukins - therapeutic use
Kidney cancer
Neoplasms - drug therapy
Neoplasms - immunology
Toxicity
Tumors
Online AccessGet full text

Cover

Abstract Interleukins 18 and 21 have been described, and the effect of each upon immune response and experimental tumors in animals has been the subject of much recent work. Both interleukins have shown antitumor effects in animals, which in some models are striking for their duration, specificity, and ability to protect against rechallenge with the same tumor. These characteristics suggest immunologic involvement in the antitumor response, and several papers suggest involvement of both innate and adaptive immune mechanisms. Recent early phase I clinical trials in human cancer patients have demonstrated evidence of clinical response. This review discusses the biology, preclinical animal tumor model data, and early clinical trial findings.
AbstractList Interleukins 18 and 21 have been described, and the effect of each upon immune response and experimental tumors in animals has been the subject of much recent work. Both interleukins have shown antitumor effects in animals, which in some models are striking for their duration, specificity, and ability to protect against rechallenge with the same tumor. These characteristics suggest immunologic involvement in the antitumor response, and several papers suggest involvement of both innate and adaptive immune mechanisms. Recent early phase I clinical trials in human cancer patients have demonstrated evidence of clinical response. This review discusses the biology, preclinical animal tumor model data, and early clinical trial findings.Interleukins 18 and 21 have been described, and the effect of each upon immune response and experimental tumors in animals has been the subject of much recent work. Both interleukins have shown antitumor effects in animals, which in some models are striking for their duration, specificity, and ability to protect against rechallenge with the same tumor. These characteristics suggest immunologic involvement in the antitumor response, and several papers suggest involvement of both innate and adaptive immune mechanisms. Recent early phase I clinical trials in human cancer patients have demonstrated evidence of clinical response. This review discusses the biology, preclinical animal tumor model data, and early clinical trial findings.
Interleukins 18 and 21 have been described, and the effect of each upon immune response and experimental tumors in animals has been the subject of much recent work. Both interleukins have shown antitumor effects in animals, which in some models are striking for their duration, specificity, and ability to protect against rechallenge with the same tumor. These characteristics suggest immunologic involvement in the antitumor response, and several papers suggest involvement of both innate and adaptive immune mechanisms. Recent early phase I clinical trials in human cancer patients have demonstrated evidence of clinical response. This review discusses the biology, preclinical animal tumor model data, and early clinical trial findings.
Author Logan, Theodore F.
Robertson, Michael J.
Author_xml – sequence: 1
  givenname: Theodore F.
  surname: Logan
  fullname: Logan, Theodore F.
– sequence: 2
  givenname: Michael J.
  surname: Robertson
  fullname: Robertson, Michael J.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/16507221$$D View this record in MEDLINE/PubMed
BookMark eNp1kV9LwzAUxYNM3Jx-AF-kIPhkNTdp09Y3Ff8MBr6455CkqWa2yWxacd_e1E0fBj7kJtz7O5dwziEaWWc1QieALwHj7MoDFEBijFk4SSh7aAIpTWJGWDEa3oTGNCvwGB16v8SYYJzjAzQGluKMEJigxcx2uq11_26sjyCPhC0jAtfRrXG1e11fRI1Wb8Ia3_jIVZFQnXE26tyXUaYL44FXtbFGifpn-hnaR2i_ErXXx9t7ihYP9y93T_H8-XF2dzOPFUlIFytWVDQnOpEsLbNUElUklZJMijKluZK4KFRFUq0kZZoKKKkgUkKm8qSkuaR0is43e1et--i173hjvNJ1Lax2vecsyzCjwAJ4tgMuXd_a8DcerEoJyQFIoE63VC8bXfJVaxrRrvmvXQHINoBqnfetrngwQQyOdK0wNQfMh2D4JhgeguFDMBwHJewo_5b_q_kG_raOPA
CitedBy_id crossref_primary_10_1371_journal_pone_0003289
crossref_primary_10_1007_s12032_023_02281_6
crossref_primary_10_1097_CJI_0000000000000220
crossref_primary_10_1158_2326_6066_CIR_13_0098
crossref_primary_10_1517_14712598_7_1_31
crossref_primary_10_1517_14728222_11_10_1261
Cites_doi 10.4049/jimmunol.160.4.1742
10.4049/jimmunol.156.11.4274
10.1084/jem.194.3.F11
10.1097/00002371-200203001-00005
10.1038/379591a0
10.1016/S1359-6349(04)80275-1
10.1084/jem.20041057
10.1200/JCO.2005.00.992
10.1189/jlb.0602313
10.1159/000386035
10.1007/s002620050345
10.1097/00002371-200203001-00008
10.1038/sj.gt.3300908
10.1111/j.0105-2896.2004.00201.x
10.1038/sj.cgt.7700552
10.1200/JCO.2005.12.157
10.1006/clin.1997.4475
10.1086/315656
10.1016/S0167-5699(97)80020-5
10.1073/pnas.200360997
10.1097/01.moh.0000141926.95319.42
10.1146/annurev.iy.12.040194.005015
10.1097/00002371-200305000-00007
10.1084/jem.187.8.1163
10.1182/blood.V99.10.3756
10.1182/blood-2002-07-2322
10.1189/jlb.72.5.856
10.1615/CritRevImmunol.v24.i4.20
10.1084/jem.194.3.343
10.1111/j.1365-2567.2004.01886.x
10.1111/j.0105-2896.2004.00199.x
10.1038/35040504
10.1096/fasebj.13.15.2195
10.1038/sj.gt.3301291
10.1097/00002371-200003000-00002
10.1002/jgm.817
10.4049/jimmunol.172.3.1540
10.4049/jimmunol.172.4.2048
10.1126/science.275.5297.206
10.1089/107999004322917007
10.4049/jimmunol.169.8.4467
10.4049/jimmunol.173.2.900
10.1016/0092-8674(94)90336-0
10.4049/jimmunol.171.2.608
10.1084/jem.194.3.355
10.1128/iai.38.2.440-443.1982
10.1111/j.1349-7006.1997.tb00409.x
10.1038/378088a0
10.4049/jimmunol.162.12.7322
ContentType Journal Article
Copyright Current Science Inc 2006.
Copyright_xml – notice: Current Science Inc 2006.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s11912-006-0046-0
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1534-6269
EndPage 119
ExternalDocumentID 16507221
10_1007_s11912_006_0046_0
Genre Journal Article
Review
GroupedDBID ---
-Y2
.86
.VR
06C
06D
0R~
0VY
1N0
203
29F
29~
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2~H
30V
4.4
406
408
40D
40E
53G
5GY
5VS
6NX
7X7
88E
8FE
8FH
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AAPKM
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYXX
AAYZH
ABAKF
ABBRH
ABDBE
ABDZT
ABECU
ABFSG
ABFTV
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABUWG
ABWNU
ABXPI
ACAOD
ACDTI
ACGFO
ACGFS
ACHSB
ACHVE
ACHXU
ACIHN
ACKNC
ACMDZ
ACMFV
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACREN
ACSTC
ACZOJ
ADBBV
ADHHG
ADHIR
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEAQA
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFHIU
AFKRA
AFLOW
AFOHR
AFQWF
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHMBA
AHPBZ
AHSBF
AHWEU
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AIXLP
AJBLW
AJRNO
AJZVZ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ATHPR
AXYYD
AYFIA
B-.
BA0
BBNVY
BDATZ
BENPR
BGNMA
BHPHI
BPHCQ
BSONS
BVXVI
C1A
CAG
CCPQU
CITATION
COF
CS3
CSCUP
CUW
DDRTE
DNIVK
DPUIP
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
ESBYG
F5P
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ7
H13
HCIFZ
HF~
HG6
HMCUK
HMJXF
HRMNR
HZ~
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
I~Z
J-C
JBSCW
JZLTJ
KOV
LK8
LLZTM
M1P
M4Y
M7P
MA-
NPVJJ
NQJWS
NU0
O9-
O9J
P9S
PF0
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
PT4
PT5
QOR
QOS
R89
R9I
RNI
ROL
RPX
RSV
RZK
S16
S1Z
S27
S37
S3B
SAP
SDH
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
TSG
TSK
TSV
TUC
U2A
U9L
UDS
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
YLTOR
ZMTXR
ZOVNA
~A9
-5E
-5G
-BR
-EM
-~C
3V.
ADINQ
CGR
CUY
CVF
ECM
EIF
GQ6
NPM
Z7U
Z81
Z82
Z87
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c242t-c69f382e4b65d75b2c94fcb6bad538cb099cf25ecb36e3a1d3a2bb17c84d38b33
IEDL.DBID 7X7
ISSN 1523-3790
IngestDate Fri Jul 11 01:20:20 EDT 2025
Fri Jul 25 11:02:54 EDT 2025
Wed Feb 19 01:44:31 EST 2025
Thu Apr 24 23:12:05 EDT 2025
Tue Jul 01 01:51:42 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c242t-c69f382e4b65d75b2c94fcb6bad538cb099cf25ecb36e3a1d3a2bb17c84d38b33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
PMID 16507221
PQID 2695228112
PQPubID 2034517
PageCount 6
ParticipantIDs proquest_miscellaneous_67706316
proquest_journals_2695228112
pubmed_primary_16507221
crossref_citationtrail_10_1007_s11912_006_0046_0
crossref_primary_10_1007_s11912_006_0046_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2006-03-00
PublicationDateYYYYMMDD 2006-03-01
PublicationDate_xml – month: 03
  year: 2006
  text: 2006-03-00
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Philadelphia
PublicationTitle Current oncology reports
PublicationTitleAlternate Curr Oncol Rep
PublicationYear 2006
Publisher Springer Nature B.V
Publisher_xml – name: Springer Nature B.V
References S Ushio (46_CR10) 1996; 156
S Ugai (46_CR50) 2003; 10
MJ Robertson (46_CR42) 2005; 23
J Brady (46_CR51) 2004; 172
MT Carrascal (46_CR38) 2003; 63
JA Gracie (46_CR13) 2003; 73
A Kaser (46_CR20) 2004; 103
KM Koch (46_CR41) 2004; 2
R Zeng (46_CR56) 2005; 201
PV Sivakumar (46_CR49) 2004; 112
K Ozaki (46_CR44) 2000; 97
T Boon (46_CR2) 1997; 18
AT Brenne (46_CR47) 2002; 99
T Osaki (46_CR24) 1998; 160
MJ Smyth (46_CR7) 2004; 202
JF Bazan (46_CR11) 1996; 379
K Yamashita (46_CR26) 2002; 9
G Wang (46_CR52) 2003; 63
H Okamura (46_CR9) 1995; 378
FM Marincola (46_CR4) 2000
P Matzinger (46_CR6) 1994; 12
MJ Robertson (46_CR40) 2004; 23
R Vankayalapati (46_CR14) 2000; 182
J Pirhonen (46_CR15) 1999; 162
FM Burnet (46_CR1) 1970; 13
H Fukumoto (46_CR34) 1997; 88
MJ Micallef (46_CR22) 1997; 57
DS Mehta (46_CR46) 2004; 202
M Neighbors (46_CR18) 2001; 194
T Tatsumi (46_CR36) 2002; 62
SL Nutt (46_CR48) 2004; 24
T Iwasaki (46_CR25) 2002; 25
DW Ju (46_CR35) 2000; 7
LJ Old (46_CR3) 1998; 187
R Cao (46_CR32) 1999; 13
YI Son (46_CR31) 2003; 26
MJ Micallef (46_CR23) 1997; 43
S Akamatsu (46_CR29) 2002; 25
T Kikuchi (46_CR28) 2000; 23
B Curti (46_CR58) 2005; 23
H Helmby (46_CR19) 2001; 194
SL Swain (46_CR21) 2001; 194
J Parrish-Novak (46_CR45) 2002; 72
JM Wigginton (46_CR30) 2002; 169
E Di Carlo (46_CR54) 2004; 172
RN Germain (46_CR5) 1994; 76
H Okamura (46_CR8) 1982; 38
T Osaki (46_CR33) 1999; 6
T Tatsumi (46_CR37) 2003; 63
K Kohno (46_CR16) 1998; 86
T Okamoto (46_CR27) 2004; 24
J Parrish-Novak (46_CR43) 2000; 408
D Cho (46_CR39) 2000; 60
Y Gu (46_CR12) 1997; 275
P Reddy (46_CR17) 2004; 11
HL Ma (46_CR53) 2003; 171
H Nakano (46_CR55) 2005; 8
A Moroz (46_CR57) 2004; 173
4921480 - Prog Exp Tumor Res. 1970;13:1-27
8293464 - Cell. 1994 Jan 28;76(2):287-99
11489954 - J Exp Med. 2001 Aug 6;194(3):355-64
12429707 - J Leukoc Biol. 2002 Nov;72(5):856-63
15548995 - Curr Opin Hematol. 2004 Nov;11(6):405-10
7477296 - Nature. 1995 Nov 2;378(6552):88-91
15035849 - J Interferon Cytokine Res. 2004 Mar;24(3):161-7
14504095 - Blood. 2004 Jan 15;103(2):648-55
14734732 - J Immunol. 2004 Feb 1;172(3):1540-7
11489953 - J Exp Med. 2001 Aug 6;194(3):343-54
12375027 - Oncol Rep. 2002 Nov-Dec;9(6):1237-44
14764669 - J Immunol. 2004 Feb 15;172(4):2048-58
12048348 - J Immunother. 2002 Mar-Apr;25 Suppl 1:S28-34
10882602 - J Infect Dis. 2000 Jul;182(1):234-9
15240677 - J Immunol. 2004 Jul 15;173(2):900-9
9067408 - Cancer Immunol Immunother. 1997 Jan;43(6):361-7
15147560 - Immunology. 2004 Jun;112(2):177-82
16097036 - J Gene Med. 2006 Jan;8(1):90-9
8011301 - Annu Rev Immunol. 1994;12:991-1045
9190110 - Immunol Today. 1997 Jun;18(6):267-8
9247607 - Jpn J Cancer Res. 1997 May;88(5):501-5
12370382 - J Immunol. 2002 Oct 15;169(8):4467-74
12543807 - Cancer Res. 2003 Jan 15;63(2):491-7
8999548 - Science. 1997 Jan 10;275(5297):206-9
15630141 - J Exp Med. 2005 Jan 3;201(1):139-48
9434792 - Clin Immunol Immunopathol. 1998 Jan;86(1):11-5
14559827 - Cancer Res. 2003 Oct 1;63(19):6378-86
12847225 - J Immunol. 2003 Jul 15;171(2):608-15
11489958 - J Exp Med. 2001 Aug 6;194(3):F11-4
10505105 - Gene Ther. 1999 May;6(5):808-15
10746544 - J Immunother. 2000 Mar-Apr;23(2):184-9
12048351 - J Immunother. 2002 Mar-Apr;25 Suppl 1:S52-60
11986233 - Blood. 2002 May 15;99(10):3756-62
9377569 - Cancer Res. 1997 Oct 15;57(20):4557-63
11081504 - Nature. 2000 Nov 2;408(6808):57-63
10825144 - Cancer Res. 2000 May 15;60(10):2703-9
12384548 - Cancer Res. 2002 Oct 15;62(20):5853-8
12806277 - J Immunother. 2003 May-Jun;26(3):234-40
11016959 - Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11439-44
12637939 - Cancer Gene Ther. 2003 Mar;10(3):187-92
15588224 - Crit Rev Immunol. 2004;24(4):239-50
15546400 - Immunol Rev. 2004 Dec;202:275-93
10593867 - FASEB J. 1999 Dec;13(15):2195-202
12554798 - J Leukoc Biol. 2003 Feb;73(2):213-24
9547328 - J Exp Med. 1998 Apr 20;187(8):1163-7
10358182 - J Immunol. 1999 Jun 15;162(12):7322-9
6216215 - Infect Immun. 1982 Nov;38(2):440-3
8628393 - Nature. 1996 Feb 15;379(6566):591
15546387 - Immunol Rev. 2004 Dec;202:84-95
8666798 - J Immunol. 1996 Jun 1;156(11):4274-9
11083476 - Gene Ther. 2000 Oct;7(19):1672-9
14695220 - Cancer Res. 2003 Dec 15;63(24):9016-22
9469432 - J Immunol. 1998 Feb 15;160(4):1742-9
References_xml – volume: 160
  start-page: 1742
  year: 1998
  ident: 46_CR24
  publication-title: J Immunol
  doi: 10.4049/jimmunol.160.4.1742
– volume: 156
  start-page: 4274
  year: 1996
  ident: 46_CR10
  publication-title: J Immunol
  doi: 10.4049/jimmunol.156.11.4274
– volume: 63
  start-page: 491
  year: 2003
  ident: 46_CR38
  publication-title: Cancer Res
– volume: 62
  start-page: 5853
  year: 2002
  ident: 46_CR36
  publication-title: Cancer Res
– start-page: 601
  volume-title: Principles and Practice of the Biologic Therapy of Cancer
  year: 2000
  ident: 46_CR4
– volume: 194
  start-page: F11
  year: 2001
  ident: 46_CR21
  publication-title: J Exp Med
  doi: 10.1084/jem.194.3.F11
– volume: 25
  start-page: S28
  issue: Suppl1
  year: 2002
  ident: 46_CR29
  publication-title: J Immunother
  doi: 10.1097/00002371-200203001-00005
– volume: 379
  start-page: 591
  year: 1996
  ident: 46_CR11
  publication-title: Nature
  doi: 10.1038/379591a0
– volume: 63
  start-page: 6378
  year: 2003
  ident: 46_CR37
  publication-title: Cancer Res
– volume: 2
  start-page: 82
  year: 2004
  ident: 46_CR41
  publication-title: Eur J Cancer
  doi: 10.1016/S1359-6349(04)80275-1
– volume: 201
  start-page: 139
  year: 2005
  ident: 46_CR56
  publication-title: J Exp Med
  doi: 10.1084/jem.20041057
– volume: 23
  start-page: 2513
  year: 2005
  ident: 46_CR42
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.00.992
– volume: 73
  start-page: 213
  year: 2003
  ident: 46_CR13
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.0602313
– volume: 9
  start-page: 1237
  year: 2002
  ident: 46_CR26
  publication-title: Oncol Rep
– volume: 13
  start-page: 1
  year: 1970
  ident: 46_CR1
  publication-title: Prog Exp Tumor Res
  doi: 10.1159/000386035
– volume: 43
  start-page: 361
  year: 1997
  ident: 46_CR23
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s002620050345
– volume: 25
  start-page: S52
  issue: Suppl1
  year: 2002
  ident: 46_CR25
  publication-title: J Immunother
  doi: 10.1097/00002371-200203001-00008
– volume: 6
  start-page: 808
  year: 1999
  ident: 46_CR33
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3300908
– volume: 202
  start-page: 84
  year: 2004
  ident: 46_CR46
  publication-title: Immunol Rev
  doi: 10.1111/j.0105-2896.2004.00201.x
– volume: 10
  start-page: 187
  issue: March
  year: 2003
  ident: 46_CR50
  publication-title: Cancer Gene Ther
  doi: 10.1038/sj.cgt.7700552
– volume: 23
  start-page: 2502
  year: 2005
  ident: 46_CR58
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.12.157
– volume: 86
  start-page: 11
  year: 1998
  ident: 46_CR16
  publication-title: Clin Immunol Immunopathol
  doi: 10.1006/clin.1997.4475
– volume: 182
  start-page: 234
  year: 2000
  ident: 46_CR14
  publication-title: J Infect Dis
  doi: 10.1086/315656
– volume: 18
  start-page: 267
  year: 1997
  ident: 46_CR2
  publication-title: Immunol Today
  doi: 10.1016/S0167-5699(97)80020-5
– volume: 97
  start-page: 11439
  year: 2000
  ident: 46_CR44
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.200360997
– volume: 11
  start-page: 405
  year: 2004
  ident: 46_CR17
  publication-title: Curr Opin Hematol
  doi: 10.1097/01.moh.0000141926.95319.42
– volume: 23
  start-page: 76
  year: 2004
  ident: 46_CR40
  publication-title: J Clin Oncol
– volume: 12
  start-page: 991
  year: 1994
  ident: 46_CR6
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.iy.12.040194.005015
– volume: 26
  start-page: 234
  year: 2003
  ident: 46_CR31
  publication-title: J Immunother
  doi: 10.1097/00002371-200305000-00007
– volume: 187
  start-page: 1163
  year: 1998
  ident: 46_CR3
  publication-title: J Exp Med
  doi: 10.1084/jem.187.8.1163
– volume: 99
  start-page: 3756
  year: 2002
  ident: 46_CR47
  publication-title: Blood
  doi: 10.1182/blood.V99.10.3756
– volume: 103
  start-page: 648
  year: 2004
  ident: 46_CR20
  publication-title: Blood
  doi: 10.1182/blood-2002-07-2322
– volume: 72
  start-page: 856
  year: 2002
  ident: 46_CR45
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.72.5.856
– volume: 24
  start-page: 239
  year: 2004
  ident: 46_CR48
  publication-title: Crit Rev Immunol
  doi: 10.1615/CritRevImmunol.v24.i4.20
– volume: 194
  start-page: 343
  year: 2001
  ident: 46_CR18
  publication-title: J Exp Med
  doi: 10.1084/jem.194.3.343
– volume: 112
  start-page: 177
  year: 2004
  ident: 46_CR49
  publication-title: Immunology
  doi: 10.1111/j.1365-2567.2004.01886.x
– volume: 202
  start-page: 275
  year: 2004
  ident: 46_CR7
  publication-title: Immunol Rev
  doi: 10.1111/j.0105-2896.2004.00199.x
– volume: 408
  start-page: 57
  year: 2000
  ident: 46_CR43
  publication-title: Nature
  doi: 10.1038/35040504
– volume: 13
  start-page: 2195
  year: 1999
  ident: 46_CR32
  publication-title: FASEB J
  doi: 10.1096/fasebj.13.15.2195
– volume: 7
  start-page: 1672
  year: 2000
  ident: 46_CR35
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3301291
– volume: 23
  start-page: 184
  year: 2000
  ident: 46_CR28
  publication-title: J Immunother
  doi: 10.1097/00002371-200003000-00002
– volume: 8
  start-page: 90
  year: 2005
  ident: 46_CR55
  publication-title: J Gene Med
  doi: 10.1002/jgm.817
– volume: 172
  start-page: 1540
  year: 2004
  ident: 46_CR54
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.3.1540
– volume: 172
  start-page: 2048
  year: 2004
  ident: 46_CR51
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.4.2048
– volume: 275
  start-page: 206
  year: 1997
  ident: 46_CR12
  publication-title: Science
  doi: 10.1126/science.275.5297.206
– volume: 24
  start-page: 161
  year: 2004
  ident: 46_CR27
  publication-title: J Interferon Cytokine Res
  doi: 10.1089/107999004322917007
– volume: 169
  start-page: 4467
  year: 2002
  ident: 46_CR30
  publication-title: J Immunol
  doi: 10.4049/jimmunol.169.8.4467
– volume: 173
  start-page: 900
  year: 2004
  ident: 46_CR57
  publication-title: J Immunol
  doi: 10.4049/jimmunol.173.2.900
– volume: 76
  start-page: 287
  year: 1994
  ident: 46_CR5
  publication-title: Cell
  doi: 10.1016/0092-8674(94)90336-0
– volume: 171
  start-page: 608
  year: 2003
  ident: 46_CR53
  publication-title: J Immunol
  doi: 10.4049/jimmunol.171.2.608
– volume: 194
  start-page: 355
  year: 2001
  ident: 46_CR19
  publication-title: J Exp Med
  doi: 10.1084/jem.194.3.355
– volume: 63
  start-page: 9016
  year: 2003
  ident: 46_CR52
  publication-title: Cancer Res
– volume: 38
  start-page: 440
  year: 1982
  ident: 46_CR8
  publication-title: Infect Immun
  doi: 10.1128/iai.38.2.440-443.1982
– volume: 57
  start-page: 4557
  year: 1997
  ident: 46_CR22
  publication-title: Cancer Res
– volume: 88
  start-page: 501
  year: 1997
  ident: 46_CR34
  publication-title: Jpn J Cancer Res
  doi: 10.1111/j.1349-7006.1997.tb00409.x
– volume: 60
  start-page: 2703
  year: 2000
  ident: 46_CR39
  publication-title: Cancer Res
– volume: 378
  start-page: 88
  year: 1995
  ident: 46_CR9
  publication-title: Nature
  doi: 10.1038/378088a0
– volume: 162
  start-page: 7322
  year: 1999
  ident: 46_CR15
  publication-title: J Immunol
  doi: 10.4049/jimmunol.162.12.7322
– reference: 16097036 - J Gene Med. 2006 Jan;8(1):90-9
– reference: 12375027 - Oncol Rep. 2002 Nov-Dec;9(6):1237-44
– reference: 12370382 - J Immunol. 2002 Oct 15;169(8):4467-74
– reference: 9377569 - Cancer Res. 1997 Oct 15;57(20):4557-63
– reference: 11081504 - Nature. 2000 Nov 2;408(6808):57-63
– reference: 9247607 - Jpn J Cancer Res. 1997 May;88(5):501-5
– reference: 9067408 - Cancer Immunol Immunother. 1997 Jan;43(6):361-7
– reference: 10825144 - Cancer Res. 2000 May 15;60(10):2703-9
– reference: 6216215 - Infect Immun. 1982 Nov;38(2):440-3
– reference: 11489954 - J Exp Med. 2001 Aug 6;194(3):355-64
– reference: 11489958 - J Exp Med. 2001 Aug 6;194(3):F11-4
– reference: 14695220 - Cancer Res. 2003 Dec 15;63(24):9016-22
– reference: 10505105 - Gene Ther. 1999 May;6(5):808-15
– reference: 15240677 - J Immunol. 2004 Jul 15;173(2):900-9
– reference: 8999548 - Science. 1997 Jan 10;275(5297):206-9
– reference: 12554798 - J Leukoc Biol. 2003 Feb;73(2):213-24
– reference: 9190110 - Immunol Today. 1997 Jun;18(6):267-8
– reference: 15588224 - Crit Rev Immunol. 2004;24(4):239-50
– reference: 11986233 - Blood. 2002 May 15;99(10):3756-62
– reference: 10882602 - J Infect Dis. 2000 Jul;182(1):234-9
– reference: 14504095 - Blood. 2004 Jan 15;103(2):648-55
– reference: 11016959 - Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11439-44
– reference: 15630141 - J Exp Med. 2005 Jan 3;201(1):139-48
– reference: 15147560 - Immunology. 2004 Jun;112(2):177-82
– reference: 14764669 - J Immunol. 2004 Feb 15;172(4):2048-58
– reference: 9547328 - J Exp Med. 1998 Apr 20;187(8):1163-7
– reference: 4921480 - Prog Exp Tumor Res. 1970;13:1-27
– reference: 12048348 - J Immunother. 2002 Mar-Apr;25 Suppl 1:S28-34
– reference: 8293464 - Cell. 1994 Jan 28;76(2):287-99
– reference: 10593867 - FASEB J. 1999 Dec;13(15):2195-202
– reference: 12806277 - J Immunother. 2003 May-Jun;26(3):234-40
– reference: 12048351 - J Immunother. 2002 Mar-Apr;25 Suppl 1:S52-60
– reference: 10746544 - J Immunother. 2000 Mar-Apr;23(2):184-9
– reference: 12637939 - Cancer Gene Ther. 2003 Mar;10(3):187-92
– reference: 8628393 - Nature. 1996 Feb 15;379(6566):591
– reference: 12429707 - J Leukoc Biol. 2002 Nov;72(5):856-63
– reference: 9469432 - J Immunol. 1998 Feb 15;160(4):1742-9
– reference: 8011301 - Annu Rev Immunol. 1994;12:991-1045
– reference: 10358182 - J Immunol. 1999 Jun 15;162(12):7322-9
– reference: 14734732 - J Immunol. 2004 Feb 1;172(3):1540-7
– reference: 11083476 - Gene Ther. 2000 Oct;7(19):1672-9
– reference: 15548995 - Curr Opin Hematol. 2004 Nov;11(6):405-10
– reference: 12384548 - Cancer Res. 2002 Oct 15;62(20):5853-8
– reference: 15546400 - Immunol Rev. 2004 Dec;202:275-93
– reference: 9434792 - Clin Immunol Immunopathol. 1998 Jan;86(1):11-5
– reference: 7477296 - Nature. 1995 Nov 2;378(6552):88-91
– reference: 14559827 - Cancer Res. 2003 Oct 1;63(19):6378-86
– reference: 12543807 - Cancer Res. 2003 Jan 15;63(2):491-7
– reference: 11489953 - J Exp Med. 2001 Aug 6;194(3):343-54
– reference: 15035849 - J Interferon Cytokine Res. 2004 Mar;24(3):161-7
– reference: 8666798 - J Immunol. 1996 Jun 1;156(11):4274-9
– reference: 15546387 - Immunol Rev. 2004 Dec;202:84-95
– reference: 12847225 - J Immunol. 2003 Jul 15;171(2):608-15
SSID ssj0020080
Score 1.7314373
SecondaryResourceType review_article
Snippet Interleukins 18 and 21 have been described, and the effect of each upon immune response and experimental tumors in animals has been the subject of much recent...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 114
SubjectTerms Animals
Antigens, Neoplasm - immunology
Antineoplastic Agents - immunology
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antitumor activity
Clinical trials
Clinical Trials as Topic
Drug Evaluation, Preclinical
Humans
Immune response
Immunity - immunology
Immunity, Innate - immunology
Interleukin-18 - immunology
Interleukin-18 - pharmacology
Interleukin-18 - therapeutic use
Interleukins
Interleukins - immunology
Interleukins - pharmacology
Interleukins - therapeutic use
Kidney cancer
Neoplasms - drug therapy
Neoplasms - immunology
Toxicity
Tumors
Title Interleukins 18 and 21: Biology, mechanisms of action toxicity, and clinical activity
URI https://www.ncbi.nlm.nih.gov/pubmed/16507221
https://www.proquest.com/docview/2695228112
https://www.proquest.com/docview/67706316
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NS9xAFH9UheKl2C9dtXYOPUmH7nxm0ovYokhBKcWFvYX5ChQ0UZOF9r_3zSS7iwe9DISZTGAm773f-wb4gkLKimkoqQrWUBkLSZ0XFgcVo_OucLl88eWVvpjJX3M1Hw1u3RhWueSJmVGH1icb-TeuS4QKBuHByd09TV2jknd1bKGxAVupdFkK6Srma4UrwaFcL5ULJKRy5dXMqXOoqHCa9WlUEen0qVx6BmxmoXO-A29GtEhOh-t9C69i8w5eX47-8Pcwywa9m7hIkS6EGWKbQDj7ToYWk_-_ktuYUnv_drcdaWsyZDGQvv2HG_Q4ndYvkyPzbGol8QFm52fXPy_o2CiBepSwPfW6rIXhUTqtQqEc96WsvdPOBuRn3iEK9DVX0Tuho7AsCMudY4U3MgjjhPgIm03bxD0g2kcVjWa-dFYGpo2RtVaWSeUlKrBmAtPlMVV-rCKemlncVOv6x-lkqyFeTuIwgePVK3dDCY2XFh8uz74aqamr1nc_gc-raaSD5NywTWwXXaWLAtEW0xPYHW5s_S0EoQXnbP_lrQ9gezCvpPiyQ9jsHxbxEwKO3h3lv-oItn6cXf3-g08zfvoIaIXTEw
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9QwFH6qphJwQewdKNQHuCAsxkscB6mqWFpNaWeEUEfqLXiLhNQmhWQE_VP9jX3OMiMO9NaLL3YcyX7P73s7wGsUUkZMfEYTbzSVIZXUOmFwSEKwzqa2LV88m6vpQn49TU434GrIhYlhlcOb2D7UvnLRRv6eqwyhgkZ4sHfxi8auUdG7OrTQ6MjiKFz-QZWt3j38gvf7hvOD_ZPPU9p3FaAOxVFDncoKoXmQViU-TSx3mSycVdZ4ZH5nETK5gifBWaGCMMwLw61lqdPSC22jARSf_E0pUJUZwean_fm37ysVLwKwtkIrF8i62cqP2ibroWrEaavBo1JKJ_9Kwv_A21bMHTyA-z0-JR87gnoIG6F8BHdmvQf-MSxaE-JZWMbYGsI0MaUnnH0gXVPLy3fkPMRk4p_1eU2qgnR5E6Sp_uIGDU7H9UM6Zjsbm1c8gcWtHOJTGJVVGbaAKBeSoBVzmTXSM6W1LFRimEycRJVZj2EyHFPu-rrlsX3GWb6uuBxPNu8i9CQOY3i7-uSiK9px0-Lt4ezznn_rfE1tY9hZTSPnRXeKKUO1rHOVpojvmBrDs-7G1v9C2Jtyzp7fvPUO3J2ezI7z48P50Qu41xl3YnTbNoya38vwEuFOY1_1NEbgx22T9TVpchB6
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LaxQxGA-lQvEivl2tNge9iKGbd6YgpViX1triwYW9jXkNFNqZ6syi_df86_olM7OLB3vrJZdkMpB8j9-X74XQW1BSlk9DQWSwhoioBXGeWxhkjM477XL54tMzdTQXXxZysYH-jrkwKaxylIlZUIfGpzfyXaYKgAoG4MFuNYRFfDuc7V_9JKmDVPK0ju00ehI5ide_wXxrPx4fwl2_Y2z2-funIzJ0GCAeVFNHvCoqblgUTsmgpWO-EJV3ytkAgsA7gE--YjJ6x1XklgZumXNUeyMCNy49hoL4v6e5pInH9GJt7CUolmu1Mg5MXKw8qjltD4wkRrItD-Ypmf6rE_8DdLPCmz1EDwakig960nqENmL9GG2dDr74J2ieHxMv4jJF2WBqsK0DZnQP9-0trz_gy5jSis_byxY3Fe4zKHDX_IENOphO68fEzDyb2lg8RfM7OcJnaLNu6vgCYeWjjEZRXzgrAlXGiEpJS4X0AoxnM0HT8ZhKP1QwT400Lsp17eV0smUfqydgmKD3q0-u-vIdty3eHs--HDi5Ldd0N0E7q2ngweRYsXVslm2ptAakR9UEPe9vbP0vAMCaMfry9q130BYQc_n1-OzkFbrfv_KkMLdttNn9WsbXgHs69yYTGEY_7pqibwBMvhNK
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interleukins+18+and+21%3A+Biology%2C+mechanisms+of+action+toxicity%2C+and+clinical+activity&rft.jtitle=Current+oncology+reports&rft.au=Logan%2C+Theodore+F.&rft.au=Robertson%2C+Michael+J.&rft.date=2006-03-01&rft.issn=1523-3790&rft.eissn=1534-6269&rft.volume=8&rft.issue=2&rft.spage=114&rft.epage=119&rft_id=info:doi/10.1007%2Fs11912-006-0046-0&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s11912_006_0046_0
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1523-3790&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1523-3790&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1523-3790&client=summon